{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"106","upperLimit":"152","value":"127"},{"groupId":"OG001","lowerLimit":"132","upperLimit":"195","value":"148"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"303"}],"units":"Participants"}],"description":"TTSP was defined as the time from randomization to the first documented symptomatic progression","dispersionType":"95% Confidence Interval","groups":[{"description":"Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily; 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment. Follow-up / Open Label phase: Subjects on sorafenib who continued the study, continued on the same dose of sorafenib as during the double-blind study.","id":"OG000","title":"Sorafenib (Nexavar, BAY43-9006)"},{"description":"Sorafenib-matching placebo tablets were orally administered twice daily (bid). Follow-up / Open Label phase: Subjects on placebo who chose to switch to sorafenib, received an oral dose of 400 mg (2 x 200 mg tablets) bid; similar to the double-blind study.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"For subjects (in the ITT population) who had not progressed symptomatically at the time of interim analysis, TTSP was censored at the date of last FACT FHSI-8 questionnaire assessment (upon an interim review by the Data Monitoring Committee on 09 Feb 2007), when the study was considered positive for its primary endpoint, OS, and was stopped early.","reportingStatus":"POSTED","timeFrame":"from randomization to the first documented symptomatic progression until an average 5.7 months later up to the data cut-off date approximately 23 months after start of enrollment","title":"Time to Symptomatic Progression (TTSP)","type":"POST_HOC","unitOfMeasure":"Days"}